← all works
Retraction notice to: PS124 – Efficacy and Safety of Induction Dosing of Vedolizumab for Reducing Biliary Inflammation in Primary Sclerosing Cholangitis (PSC) in Individuals with Inflammatory Bowel Disease [J Hepatol 64 (2016) S199]
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Canadian affiliationAn author listed a Canadian institution. This is the only route the usual frame has.
Post-publication record
OpenAlex flags this work as retracted, but it carries no matching Retraction Watch record in this frame.
Abstract
No abstract. This is not a gap in this database — OpenAlex has none either. 23.3% of the frame is in this state, and the screen finds HALF as much metaresearch here, so the absence is a measured bias rather than a missing field.
The record
- Venue
- Journal of Hepatology
- Topic
- Liver Diseases and Immunity
- Field
- Medicine
- Canadian institutions
- Alberta Health ServicesUniversity of Calgary
- Funders
- —
- Keywords
- VedolizumabPrimary sclerosing cholangitisMedicineInflammatory bowel diseaseDosingGastroenterologyUlcerative colitisInternal medicineNoticeInflammationDisease
- Has abstract in OpenAlex
- no